Role of the impairment of oxidative metabolism in pathogenesis of lower urinary tract symptoms with benign prostatic hyperplasia and their treatment by α1-adrenoblockers alfuzosin

Mitochondrion

Volumn 3, Issue 2, 2003, Pages 67-73

  Vishnevsky, E L ^a   Kondrashova, M N ^b   Pushkar, D Y ^a   Vishnevsky, E ^a   Demidov, A A ^a   Sirota, T V ^b   Temnov, A V ^b   Khunderyakova, N V ^b   Zakharchenko, M V ^b   Kosyakova, N I ^c  

^a Moscow Industrial University   (Russian Federation)

^b INSTITUTE OF THEORETICAL AND EXPERIMENTAL BIOPHYSICS   (Russian Federation)

^c Clinical Center   (Russian Federation)

Author keywords

1 Adrenoblockers; Alfuzosin; Antioxidant activity; Benign prostatic hyperplasia; Catecholamines; Detrusor; Energy metabolism; Lower urinary tract symptoms; Mitochondria; Oxidative metabolism; Reactive oxygen species; Succinate dehydrogenase; Urinary bladder

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIOXIDANT; DOXAZOSIN; NICERGOLINE; PRAZOSIN; SUCCINATE DEHYDROGENASE; TAMSULOSIN; TERAZOSIN;

ADULT; AEROBIC METABOLISM; AGED; ANTIOXIDANT ACTIVITY; BLADDER CAPACITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; ENERGY METABOLISM; ENZYME ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SYMPTOMATOLOGY; URETHRA;

EID: 0141461417     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-7249(03)00061-8     Document Type: Review

References (17)

1. Bartach G. (Ed.), The Role of Alpha Blockers in Benign Prostatic Hyperplasia 1997 55-65
2. Chapple C.R. Introduction and conclusions Eur. Urol. 39 Suppl. 3 2001 1-6
3. Chapple C.R. Pharmacotherapy for benign prostatic hyperplasia-the potential for α1-adrenoreceptor subtype-specific blockade Br. J. Urol. 1 1998 34-47
4. Coffey, D. Chairman's highlights. 2001 Urology Summit Meeting, New York.
5. Hayhoe F.G.J. Quaglino D. Haematological Cytochemistry 1980 Churchill Livingstone Edinburgh, London and New York
6. Lepor, H., 1996. Long term evaluation of tamsulusin, a prostate selective alpha1 antagonist. J. Urol., 155 (suppl): 585 A (abs. 1099).
7. Lopatkin N.A. Benign Prostatic Hyperplasia (in Russian), Moscow 1997
8. Lopatkin N.A. Peripanova T.S. Clinical experience of treatment patients with benign prostatic hyperplasia by alpha1-adrenoblocker alfuzosin (in Russian) J. Urol. Nephrol. 5 1997 14-17
9. Loran O.B. Vishnevsky E.L. Vishnevsky A.E. Role of detrusor hypoxia in pathogenesis of LUTS in patients with benign prostatic hyperplasia (in Russian) J. Urol. Nephrol. 6 1996 33-37
10. Loran, O.B., Vishnevsky, E.L., Vishnevsky, A.E. Treatment for LUTS in patients with benign prostatic hyperplasia by α-adrenoblockers (in Russian). Moscow, 1998.
11. Medvedev, Y.V., Tolstoi, A.D. Hypoxia and Free Radicals in Development of Pathological States of the Organism. Moscow, Terra-Calender, 2000 (in Russian).
12. Polewsky K. Biochem. Biophys. Acta 1523 2000 56-64
13. Sirota T.V. The new approach to study of adrenaline autooxidation and its application for superoxide dismutase activity measurement (in Russian) Voprosy Med. Chim. 45 1999 263-272
14. Speakman M.J. Lower urinary tract symptoms suggestive of benign prostatic obstruction: what is the available evidence for rational management? Eur. Urol. 39 Suppl. 3 2001 6-12
15. Starkov A.A. Simonyam R. Dedukhova V. Mansurova S. Palamarchuk L.A. Skulachev V.P. Regulation of the energy coupling in mitochondria by some steroid and thyroid hormones (in Russian) Biochem. Biophys. Acta 1318 1997 173-183
16. Vishnevsky, A.E. Role of detrusor hypoxia in pathogenesis of LUTS in patients with benign prostatic hyperplasia and substantiation for their conservative treatment. Ph.D Thesis. Moscow, 1998 (in Russian).
17. Zhirnikova, M.L., Vinarov, A.Z., Mashkovsky, M.D., Pytel', Yu.A. Alpha-adrenoblockers in therapy of patients with prostate adenoma (in Russian). Meeting of Russian Urological Society, Saratov 1994, pp. 88-96.